Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery

Author(s): Francesco Marchesi, Andrea Mengarelli

Journal Name: Current Medicinal Chemistry

Volume 23 , Issue 21 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


To date, two kinds of Granulocyte Colony-Stimulating Factors (G-CSF) have been approved for autologous peripheral blood hematopoietic stem cell (PBSCs) mobilization and posttransplant hematologic recovery after high-dose chemotherapy: filgrastim (originator and biosimilar) and lenograstim. Biosimilar filgrastim has been approved on the basis of comparable efficacy and safety in clinical studies where it has been used as chemotherapy-induced febrile neutropenia prophylaxis, but no specific pre-registration studies have been published in the transplant setting. Hence, there is still general skepticism about the role of biosimilar G-CSFs in this setting of patients. This review of biochemical, pre-clinical and clinical data suggests significant comparability of biosimilar filgrastim with both originator filgrastim and lenograstim in autologous PBSCs mobilization and post-autograft hematologic recovery.

Keywords: Autologous stem cell transplant, Biosimilar filgrastim, Hematologic recovery, Lenograstim, Originator filgrastim, Peripheral blood hematopoietic stem cell mobilization.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 17 May, 2016
Page: [2217 - 2229]
Pages: 13
DOI: 10.2174/0929867323666160517115907
Price: $65

Article Metrics

PDF: 102